We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00351962
First Posted: July 13, 2006
Last Update Posted: September 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AHS Cancer Control Alberta
July 11, 2006
July 13, 2006
September 21, 2017
September 2006
July 2014   (Final data collection date for primary outcome measure)
Dose-limiting toxicity as defined by CTCAE V3 grade 4 or 5. [ Time Frame: At the completion of accrual, an analysis with respect to acute toxicity will be performed after all patients have been followed a minimum of 90 days from the start of RT. ]
Each schedule will be evaluated according to the occurrence of DLTs observed.
Dose-limiting toxicity as defined by CTCAE V3 grade 4 or 5.
Complete list of historical versions of study NCT00351962 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
Medically inoperable lung cancer or metastatic lung tumours will be treated with fractionated stereotactic radiation using a schedule of 1) 12 Gy x 4 treatments or 2) 6 Gy x 10 treatments.

You will be positioned in a special body mould while you are lying in the treatment position. This ensures that you are treated in the exact position each time. A soft plastic sheet may be placed over your body from the chest down. A vacuum device may be used to apply the sheet gently over you. This mild compression will ensure that you can breathe comfortably but will minimize any movement which may affect the accuracy of your treatments.

A CT (computed tomography) scan will be done for your treatment planning. The CT scan will take approximately 45 minutes. In some cases, intravenous dye may be administered during the CT scan. You will be asked to hold your breath for a short time during the CT scan. If you are unable to hold your breath comfortably, the scan will be performed during your normal breathing cycle. In some cases, your doctor may also order a PET (positron emission tomography) scan. The treatment planning to be done by your oncologist and physicist will take approximately one to two weeks. After that is completed, your treatments will begin. Each treatment will take about 30 minutes.

If the CT scans show that there is a lot of movement of your lung cancer due to breathing motion, your oncologist may recommend the insertion of a "fiducial" marker to help guide your treatments. An additional consent form will be obtained prior to this procedure. The "fiducial" marker is a tiny gold or stainless steel coil measuring about one inch long. It would be inserted into your lung in or next to the tumour by a respirologist via bronchoscopy under sedation. The procedure would take approximately 30 minutes, and you would be in hospital for about 4 hours. You would meet the respirologist in the clinic in consultation prior to the procedure so that he/she can tell you more about the procedure and assess your case in details to determine if it is safe for you to undergo the procedure. The insertion of the fiducial marker is considered part of your clinical care and a separate consent will be required prior to this procedure. You may choose not to undergo this procedure but still participate in this study. In some cases, your respirologist may have already inserted a fiducial marker at the time of diagnostic bronchoscopy after discussions with yourself and your radiation oncologist. The "fiducial" marker would be used to guide your radiation treatments during your normal breathing cycle.

You will be assigned into one of the two study groups described below depending on the location of your tumour:

Schedule I (10 fractions): You will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.

Schedule II (4 fractions): You will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Lung Neoplasms
  • Lung Cancer
Procedure: Fractionated Stereotactic Radiotherapy
  • Experimental: Schedule I (10 fractions)
    Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
    Intervention: Procedure: Fractionated Stereotactic Radiotherapy
  • Experimental: Schedule II (4 fractions)
    Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
    Intervention: Procedure: Fractionated Stereotactic Radiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
July 2, 2014
July 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • non-small cell lung cancer less than 6cm; no mediastinal or distant metastases
  • Open to Alberta,Canada Residents

Exclusion Criteria:

  • tumour size greater than 6cm; inadequate pulmonary function(ie. FEV1 less than 0.8 L), Karnofsky performance status less than 70, multiple co-morbid conditions
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00351962
20131
Not Provided
Not Provided
Not Provided
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Not Provided
Principal Investigator: Harold P Lau, MD Tom Baker Cancer Center
AHS Cancer Control Alberta
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP